DGX250117P135000
- 0.19
- 0.000.00%
Quest Diagnostics Newsroom
Mizuho Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating, Announces Target Price $177
Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management
Mizuho Adjusts Price Target on Quest Diagnostics to $177 From $174, Keeps Outperform Rating
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services
Is Quest Diagnostics (NYSE:DGX) Using Too Much Debt?
Quest Diagnostics Deal Sends Mainz Higher
Express News | Mainz Biomed NV - Quest to Provide Lab Services for Mainz Biomed's Reconaasense Study
Express News | Mainz Biomed Forms Agreement With Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
Dow Breaks Downward Spiral, with FOMC Rate Cut on Deck | Live Stock
Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today
Quest Diagnostics Advances Environmental Stewardship With Renewable Energy Initiatives, Waste Reduction, and ISO 14001 Certifications in 2023
Health-care Sector Faces Mixed Prospects in 2025, Morgan Stanley Says
Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock
Tesla To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Tuesday
This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Morgan Stanley Upgrades Quest Diagnostics(DGX.US) to Buy Rating, Raises Target Price to $172
Morgan Stanley Upgrades Quest Diagnostics to Overweight From Equalweight, Adjusts Price Target to $172 From $145